Abstract
Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-α) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-α therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-α and anti-TNF-α therapy in patients with UC and diverticular disease associated colitis.
Keywords: Biological therapy, ulcerative colitis, diverticular disease associated colitis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis
Volume: 7 Issue: 3
Author(s): C. Hassan, A. Zullo, V. De Francesco, S. M.A. Campo, S. Morini, C. Panella and E. Ierardi
Affiliation:
Keywords: Biological therapy, ulcerative colitis, diverticular disease associated colitis
Abstract: Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-α) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-α therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-α and anti-TNF-α therapy in patients with UC and diverticular disease associated colitis.
Export Options
About this article
Cite this article as:
Hassan C., Zullo A., De Francesco V., Campo M.A. S., Morini S., Panella C. and Ierardi E., Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187153007781662530
DOI https://dx.doi.org/10.2174/187153007781662530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression Profiling of Estrogen Responsive Genes Using Genomic and Proteomic Techniques for the Evaluation of Endocrine Disruptors
Current Pharmacogenomics Liposomes: A Review of Manufacturing Techniques and Targeting Strategies
Current Nanoscience A Microextraction Liquid-Chromatographic Determination of Aristolochic Acid I in Urine, Flour, and Aristolochiaceae Fruit
Current Pharmaceutical Analysis Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer
Current Drug Targets Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Lycorine and its Derivatives for Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Fluorescent Carbon Dots as Prospective Nanoagents for Imaging-assisted Biomedical Applications
Current Medicinal Chemistry Extraction, Isolation and Analysis of Chondroitin Sulfate Glycosaminoglycans
Recent Patents on Food, Nutrition & Agriculture Prediction of Aquatic Toxicity of Benzene Derivatives to Tetrahymena pyriformis According to OECD Principles
Current Pharmaceutical Design In vivo Distribution of Tiotropium in a Rodent Model Utilizing AP-SMALDI Mass Spectrometry Imaging
Current Analytical Chemistry Patented Aptamers for C-Reactive Protein Detection: A Review About their Use in Clinical Diagnostics
Recent Patents on DNA & Gene Sequences Synthesis and Anti-cancer Activities of Apigenin Derivatives
Medicinal Chemistry Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Synthesis of A/B-Ring Partial Analogs of Bruceantin as Potential Antimalarial Agents
Medicinal Chemistry Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Imaging Localised Hydrogen Peroxide Production in Living Systems
Current Chemical Biology Quantification of Sulfotransferases 1A1 and 1A3/4 in Tissue Fractions and Cell Lines by Multiple Reaction Monitoring Mass Spectrometry
Drug Metabolism Letters Study on Caspase-Induced Mitochondrial Dysfunction by Anticancer Drugs
Current Drug Therapy Shikimate Kinase, a Protein Target for Drug Design
Current Medicinal Chemistry